Four new medicines and three biosimilars recommended for approval in Europe

12 November 2016
biosimilars_samples_large

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended four new medicines and three biosimilars for approval at its November meeting.

The CHMP recommended granting a marketing authorization for Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with hemophilia A, from CSL Behring, a subsidiary of Australia’ CSL Limited (ASX: CSL). The drug was approved by theUS Food and Drug Administration in May this year.

Vemlidy (tenofovir alafenamide) received a positive opinion from the CHMP for the treatment of chronic hepatitis B from US biotech firm Gilead Sciences (Nasdaq: GILD). The recommendation comes just a day after the US FDA approved the drug for marketing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars